
    
      OBJECTIVES:

      Primary

        -  Determine the response rate in patients with newly diagnosed, previously untreated
           extensive stage small cell lung cancer treated with irinotecan and carboplatin.

      Secondary

        -  Determine the progression-free and overall survival of patients treated with this
           regimen.

      OUTLINE: This is a multicenter study.

      Patients receive irinotecan IV and carboplatin IV on days 1 and 8. Treatment repeats every 21
      days for 6 courses.

      PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study.
    
  